Michael Jon Brown Sells 1,700 Shares of DexCom (NASDAQ:DXCM) Stock

Key Points

• EVP Michael Jon Brown sold 1,700 DexCom shares on April 15 at an average price of $63.04 for $107,168 (he also sold 1,700 on March 16 at $64.85), reducing his stake by 1.51% to 111,204 shares valued at about $7.01 million; the April trade was executed under a pre-arranged Rule 10b5-1 plan.
• Company results and analyst view: DexCom beat estimates with $0.68 EPS (vs. $0.65) and $1.26B revenue (+13.1% YoY) last quarter, and analysts hold a consensus "Moderate Buy" rating with a $86.50 price target.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the firm's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The shares were sold at an average price of $64.85, for a total value of $110,245.00.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $0.31 during mid-day trading on Thursday, reaching $61.23. 5,745,421 shares of the company's stock were exchanged, compared to its average volume of 3,723,623. The firm has a 50-day moving average price of $67.48 and a two-hundred day moving average price of $66.75. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The firm has a market capitalization of $23.56 billion, a price-to-earnings ratio of 29.16, a price-to-earnings-growth ratio of 1.20 and a beta of 1.55. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the previous year, the firm earned $0.45 earnings per share. DexCom's revenue was up 13.1% on a year-over-year basis. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on DXCM shares. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. BTIG Research restated a "buy" rating and set a $85.00 price target on shares of DexCom in a report on Monday, March 9th. Morgan Stanley reissued an "overweight" rating on shares of DexCom in a research report on Monday, January 12th. Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the company a "buy" rating in a research report on Friday, February 13th. Finally, Weiss Ratings upgraded DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $86.50.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Trust Co. of Vermont raised its holdings in shares of DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company's stock valued at $74,000 after buying an additional 145 shares during the period. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock worth $30,000 after acquiring an additional 147 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of DexCom by 2.5% during the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company's stock worth $474,000 after acquiring an additional 169 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company's stock valued at $61,000 after purchasing an additional 178 shares during the last quarter. Finally, Inspire Investing LLC lifted its holdings in shares of DexCom by 6.1% in the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company's stock valued at $211,000 after purchasing an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.